(Stroke. 1997;28:214-218.)
© 1997 American Heart Association, Inc.
Articles |
When Is Thrombolysis Justified in Patients With Acute Ischemic Stroke?
A Bioethical Perspective
the Departments of Neurology (A.J.F.) and Bioethics (G.K.), The Cleveland Clinic Foundation (Ohio).
Correspondence to Anthony J. Furlan, MD, Cerebrovascular Center Department of Neurology, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195-5226. E-mail furlana@ccsmmmtp.ccf.org.
Background Thrombolytic therapy for acute ischemic stroke raises several unsettled bioethical issues related to risk versus benefit. Excluding the National Institutes of Neurological Disorders and Stroke (NINDS) rt-PA trial, the risk of intracerebral hemorrhage averages 10.3%, and there is a 44% increase in the odds of death among fibrinolysis-treated patients. Some investigators have suggested that as yet unidentified subgroups may benefit despite an increased early risk of hemorrhage and death, while others have warned that the widespread use of thrombolysis cannot currently be recommended despite recent Food and Drug Administration approval. The NINDS rt-PA trial showed a net benefit, but the relative risk to benefit ratio in individual patients is uncertain because of incomplete subgroup analysis. We explore these and related issues by applying the bioethical principle of justification to the selection of stroke patients for thrombolysis.
Summary of Comment Justification of a therapy rests on the criteria of safety, efficacy (net benefit under ideal conditions), effectiveness (net benefit under routine conditions), efficiency (cost-effectiveness or cost benefit), and outcome (proportionality and informed consent). The ethical principal of proportionality states that positive outcomes must be proportional to negative outcomes; only the NINDS trial sets equipoise between risk and benefit. The relative risk to benefit ratio and cost-effectiveness of thrombolysis will likely vary among treating physicians and patient subgroups. Although some potential selection factors such as early CT changes, National Institutes of Health Stroke Scale score >22, and age >77 years have been identified, it is not yet possible to predict response to treatment in individual patients. The effectiveness of thrombolysis outside of a clinical trial has not yet been demonstrated, and it is not clear that thrombolysis is cost-effective for all potential patient subgroups.
Conclusions No stroke thrombolysis regimen has met all five justification criteria. Proportional outcome standards that take into account patient preferences must be established. The risk to benefit ratio of thrombolysis in patient subgroups requires clarification and should incorporate cost-efficiency analyses. These issues should be kept in mind when considering thrombolysis therapy in patients with acute ischemic stroke and when designing clinical trials.
Key Words: cerebral ischemia • ethics, medical • thrombolysis
This article has been cited by other articles:
 |
|
 |
|
  S. R. White-Bateman, H. C. Schumacher, R. L. Sacco, and P. S. Appelbaum Consent for Intravenous Thrombolysis in Acute Stroke: Review and Future Directions Arch Neurol, June 1, 2007; 64(6): 785 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, May 22, 2007; 115(20): e478 - e534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Adams Jr, G. del Zoppo, M. J. Alberts, D. L. Bhatt, L. Brass, A. Furlan, R. L. Grubb, R. T. Higashida, E. C. Jauch, C. Kidwell, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke, May 1, 2007; 38(5): 1655 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Moodie, R. Carter, C. Mihalopoulos, A. G. Thrift, B. R. Chambers, G. A. Donnan, and H. M. Dewey Trial Application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to Assist Priority Setting in Stroke Stroke, May 1, 2004; 35(5): 1041 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Seitz, M. Hamzavi, U. Junghans, P. A. Ringleb, C. Schranz, and M. Siebler Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Stroke: Preliminary Observations Stroke, August 1, 2003; 34(8): 1932 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Neumann-Haefelin, G. Brinker, U. Uhlenkuken, F. Pillekamp, K-A. Hossmann, and M. Hoehn Prediction of Hemorrhagic Transformation After Thrombolytic Therapy of Clot Embolism: An MRI Investigation in Rat Brain Stroke, May 1, 2002; 33(5): 1392 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Nabavi, A. Cenic, S. Henderson, A. W. Gelb, T.-Y. Lee, and G. A. Rosenberg Perfusion Mapping Using Computed Tomography Allows Accurate Prediction of Cerebral Infarction in Experimental Brain Ischemia Editorial Comment Stroke, January 1, 2001; 32(1): 175 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Tong, A. Adami, M. E. Moseley, and M. P. Marks Relationship Between Apparent Diffusion Coefficient and Subsequent Hemorrhagic Transformation Following Acute Ischemic Stroke Stroke, October 1, 2000; 31(10): 2378 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pantoni, C. Sarti, and D. Inzitari Cytokines and Cell Adhesion Molecules in Cerebral Ischemia : Experimental Bases and Therapeutic Perspectives Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 503 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Horowitz Thrombolytic Therapy in Acute Stroke: Neurologists, Get Off Your Hands! Arch Neurol, February 1, 1998; 55(2): 155 - 157. [Full Text] [PDF]
|
|
|
|
|
|
T. N. t-P. S. S. Group Generalized Efficacy of t-PA for Acute Stroke : Subgroup Analysis of the NINDS t-PA Stroke Trial Stroke, November 1, 1997; 28(11): 2119 - 2125. [Abstract] [Full Text]
|
|
|
|
|
|
R. F. Gillum and C. T. Sempos The End of the Long-term Decline in Stroke Mortality in the United States? Stroke, August 1, 1997; 28(8): 1527 - 1529. [Full Text]
|
|